For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

We are availabe to talk to you Monday - Friday 9am - 5pm

GDPR text - this is just a placeholder until correct text is inserted.

Have a member of our team call you back.

GDPR text - this is just a placeholder until correct text is inserted.

You can email us your enquiry by completing the form below.

Donec nisl risus, mattis ut, porttitor vitae, lobortis sagittis, lacus. Nullam neque ligula, congue at, fringilla at, consequat vitae, nulla. Nam ut felis. Curabitur imperdiet ligula a leo molestie malesuada. Praesent neque tortor, placerat accumsan, imperdiet non, iaculis at, mauris. In lacus quam, semper in, ullamcorper et, hendrerit id, pede. Nulla pretium sodales nunc.

Quisque augue quam, pulvinar in, accumsan et, pellentesque sed, ligula. Proin viverra, quam et aliquam molestie, turpis enim pellentesque eros, nec varius sem est id sapien. Aliquam at orci. Cras enim. Nam magna quam, elementum a, aliquet at, eleifend id, lacus. Donec et odio id quam laoreet suscipit.

Quisque ac ante. Aenean in neque. Suspendisse aliquet tincidunt pede. Duis mi. Morbi sapien. Cras posuere interdum nisl. Proin ac eros. Integer sit amet odio. Nullam nec velit dapibus augue condimentum egestas. Phasellus quis odio. Sed semper aliquet risus. Integer gravida vulputate sem. Praesent eu mauris. Fusce consequat congue dui. Vivamus quis metus non dui pellentesque tempor.

Davy Research

Malin Corporation

Update on Viamet investment

Oct 23 2026, 07:50 IST/BST
Colin Grant
Company Report
6 page(s)

Sectors : Healthcare

Companies : Malin Corporation

Ratings and price correct at time of issue.

Malin Corporation

Closing Price: 690c
RATING 29/09/15
OUTPERFORM
PREVIOUS RATING N/A

Person's Name

Colin Grant

Analyst

DAVY VIEW

Malin has provided an update on its investment in Viamet, which was previously acquired by Mycovia. Mycovia had submitted a new drug application in the US but this has not been approved. Malin has now indicated that it expects to write off the value of its investment in Viamet in its H2 results, reducing its portfolio NAV.

View full article

Download full report with analyst certification and important disclosures

Oct 23 2026, 07:50 IST/BST